Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo

Journal of the American College of Cardiology

Volumn 32, Issue 3, 1998, Pages 780-786

  Yamawaki, Tohru ^a   Shimokawa, Hiroaki ^a   Kozai, Toshiyuki ^a   Miyata, Kenji ^a   Higo, Taiki ^a   Tanaka, Eriko ^a   Egashira, Kensuke ^a   Shiraishi, Tadayoshi ^b   Tamai, Hideo ^c   Igaki, Keiji ^d   Takeshita, Akira ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KANEKA CORPORATION   (Japan)

^c SHIGA MEDICAL CENTER FOR ADULTS   (Japan)

^d Igaki Medical Planning Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CYANO 3 ETHOXY 4 HYDROXY 5 (PHENYLTHIOMETHYL)CINNAMAMIDE; POLYLACTIC ACID; PROTEIN TYROSINE KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADATION; CORONARY ARTERY CIRCUMFLEX BRANCH; CORONARY ARTERY OBSTRUCTION; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG RELEASE; DRUG UPTAKE; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NONHUMAN; PRIORITY JOURNAL; RESTENOSIS; STENT; SWINE; TISSUE LEVEL; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; CINNAMATES; CORONARY DISEASE; CORONARY VESSELS; DRUG IMPLANTS; ENZYME INHIBITORS; EQUIPMENT DESIGN; LACTIC ACID; MALE; PLATELET AGGREGATION INHIBITORS; POLYMERS; PROTEIN-TYROSINE KINASES; RECURRENCE; STENTS; SULFIDES; SWINE;

EID: 0031689471     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(98)00312-X     Document Type: Article

References (35)

1. Popma J.J., Topol E.J. Factors influencing restenosis after coronary angioplasty. Am J Med. 88:1990;1-16N.
2. Hillegass A.B., Ohman E.M., Calif R.M. Restenosis the clinical issues . Topol E.J. Textbook of Interventional Cardiology. 2nd ed. 1994;415-435 WB Saunders, Philadelphia.
3. Currier J.W., Faxon D.P. Restenosis after percutaneous transluminal coronary angioplasty have we been aiming at the wrong target? J Am Coll Cardiol. 25:1995;516-520.
4. Shatz R.A. A view of vascular stents. Circulation. 79:1989;445-457.
5. Serruys P.W., Jaegere P.D., Kiemeneij F., et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 331:1994;489-495.
6. Waller B.F., Pinkerton C.A., Orr C.M., et al. Restenosis 1 to 24 months after clinically successful coronary balloon angiography a necropsy study of 20 patients . J Am Coll Cardiol. 17:1991;58-70B.
7. Liu M.W., Roubin G.S., King S.B.I. Restenosis after coronary angiography potential biologic determination and role of intimal hyperplasia . Circulation. 79:1989;1374-1387.
8. Ross R. The pathogenesis of atherosclerosis a perspective for the 1990s . Nature. 362:1994;801-809.
9. Grotendorst G.R., Chang T., Seppa H.E., Kleinman H.K., Martin G.R. Platelet-derived growth factor is a chemoattractant for vascular smooth muscle cells. J Cell Physiol. 113:1982;261-266.
10. Banskota N.K., Taub R., Zellner K., Olsen P., King G.L. Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I. Diabetes. 38:1989;123-129.
11. Senior R.M., Griffin G.L., Mecham R.P. Chemotactic responses of fibroblasts to tropoelastin and elastin-derived peptides. J Clin Invest. 70:1982;614-618.
12. Postlethwaite A.E., Seyer J.M., Kang A.H. Chemotactic attraction of human fibroblasts to type I, II, and III collagens and collagen-derived peptides. Proc Natl Acad Sci USA. 75:1978;871-875.
13. Ullrich A., Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell. 61:1990;203-212.
14. Wang J.Y.J., McWhiter J.R. Tyrosine-kinase-dependent signaling pathways. Trends Cardiovasc Med. 4:1994;264-270.
15. Ito A., Shimokawa H., Kadokami T., et al. Tyrosine kinase inhibitor suppresses coronary arteriosclerotic changes and vasospastic responses induced by chronic treatment with interleukin-1β in pigs in vivo. J Clin Invest. 96:1995;1288-1294.
16. Kozai T., Shimokawa H., Fukumoto Y., et al. Tyrosine kinase inhibitor markedly suppresses the development of coronary lesions induced by long-term treatment with platelet-derived growth factor in pigs in vivo. J Cardiovasc Pharmacol. 29:1997;536-545.
17. Fukumoto Y., Shimokawa H., Kozai T., et al. Tyrosine kinase inhibitor suppresses the (re)stenotic changes of the coronary artery after balloon injury in pigs. Cardiovasc Res. 32:1996;1131-1140.
18. Muller D.W.M., Topol E.J. Implantable devices in the coronary artery from metal to genes . Trends Cardiovasc Med. 1:1991;225-232.
19. Wilensky R.L., March K.L., Gradus-Pizlo I., Speady A.J., Hathaway D.R. Methods and devices for local drug delivery in coronary and peripheral arteries. Trends Cardiovasc Med. 3:1993;163-170.
20. Labinaz M., Zidar J.P., Stack R.S., Phillips H.R. Biodegradable stents The future of interventional cardiology? J Intervent Cardiol. 8:1995;395-405.
21. Peng T., Gibula P., Yao K.-D., Goosen M.F.A. Role of polymers in improving the results of stenting in coronary arteries. Biometerials. 17:1996;685-694.
22. Aggarwal R.K., Ireland D.C., Azrin M.A., Ezekowitz M.D., Bono D.P., Gershlick A.H. Antithrombotic potential of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor antibody. Circulation. 94:1996;3311-3317.
23. Guzman L.A., Labhasetwar V., Song C., et al. Local intraluminal infusion of biodegradable polymeric nanoparticles A novel approach for prolonged drug delivery after balloon angioplasty . Circulation. 94:1996;1441-1448.
24. Scheerder I.D., Wang K., Wilczek K., et al. Experimental study of thrombogenicity and foreign body reaction induced by heparin-coated coronary stents. Circulation. 95:1997;1549-1553.
25. Kulkarni R.K., Pani K.C., Neuman C., Leonard F. Polylactic acid for surgical implants. Arch Surg. 93:1966;839-843.
26. Heino A., Naukkarinen A., Kulju T., Tormala P., Pohjonen T., Makela E.A. Characteristics of poly(L-)lactic acid suture applied to facial closure in rat. J Biomed Mater Res. 30:1996;187-192.
27. Bostman O.M. Absorbable implants for the fixation of fractures. J Bone Joint Surg. 73A:1991;148-153.
28. Schakenraad J.M., Oosterbaan J.A., Nieuwenhuis P., et al. Biodegradable hollow fibers for the controlled release of drugs. Biomaterials. 9:1988;116-120.
29. Schakenraad J.M., Hardonk M.J., Feijen J., Molenaar I., Nieuwenhuis P. Enzymatic activity toward poly(L-lactic acid) implants. J Biomed Mater Res. 24:1990;529-545.
30. Agrawal C.M., Haas K.F., Leopold D.A., Clark H.G. Evaluation of poly (L-lactic acid) as a material for intravascular polymeric stents. Biomaterials. 13:1992;176-182.
31. Tamai H., Doi T., Hsu Y.-S., et al. Initial and long-term results of biodegradable polymer stent in canine coronary artery. J Invasive Cardiol. 7:1995;9. (Abstr).
32. Shiraishi T., Domoto T., Imai N., Shimada Y., Watanabe K. Specific inhibitors of tyrosine-specific protein kinase, synthetic 4-hydroxycinnamamide derivatives. Biochem Biophys Res Commun. 147:1987;322-328.
33. Woodward S.C., Brewer P.S., Moatamed F., Schindler A., Pitt C.G. The intracellular degradation of poly (ε-caprolactone). J Biomed Mater Res. 19:1985;437-444.
34. Giessen W.J., Lincoff A.M., Schwartz R.S., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation. 94:1996;1690-1697.
35. Lincoff A.M., Furst J.G., Ellis S.G., Tuch R.J., Topol E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol. 29:1997;808-816.